Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
15 hedge funds and large institutions have $37.3M invested in Anebulo Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 0 closing their positions.
163% more capital invested
Capital invested by funds: $14.2M → $37.3M (+$23.1M)
58.72% more ownership
Funds ownership: 28.32% → 87.04% (+59%)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
15% more funds holding
Funds holding: 13 → 15 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
+$16.6M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$4.16M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.16M |
| 4 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$98.3K |
| 5 |
Morgan Stanley
New York
|
+$34.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
LVW Advisors
Pittsford,
New York
|
-$14K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.22K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$234 |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$234 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $26M | +$16.6M | +10,101,010 | +188% |
|
|
NCM
2
Nantahala Capital Management
New Canaan,
Connecticut
| $5.1M | +$4.16M | +2,525,252 | +494% |
|
|
MP
3
Mangrove Partners
Greenwich,
Connecticut
| $3.64M | +$4.16M | +2,525,252 | New |
|
|
LA
4
LVW Advisors
Pittsford,
New York
| $1.06M | -$14K | -8,523 | -1% |
|
|
5
Morgan Stanley
New York
| $706K | +$34.2K | +20,775 | +5% |
|
|
IC
6
Ikarian Capital
Dallas,
Texas
| $265K | -$234 | -142 | -0.1% |
|
7
Vanguard Group
Malvern,
Pennsylvania
| $259K | – | – | – |
|
8
Geode Capital Management
Boston,
Massachusetts
| $153K | +$5.85K | +3,551 | +4% |
|
|
9
Luther King Capital Management (LKCM)
Fort Worth,
Texas
| $100K | +$98.3K | +59,662 | New |
|
|
BFM
10
Boothbay Fund Management
New York
| $31.6K | -$234 | -142 | -0.7% |
|
11
BlackRock
New York
| $6.6K | +$40 | +24 | +0.6% |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $5.59K | +$1.04K | +632 | +23% |
|
13
Bank of America
Charlotte,
North Carolina
| $128 | – | – | – |
|
|
14
UBS Group
Zurich,
Switzerland
| $42 | -$1.22K | -738 | -97% |
|
15
JP Morgan Chase
New York
| $15 | – | – | – |
|
ANEB Hedge Fund Activity: Q4 2024 in Review
15 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q4 2024, worth a combined $37.3M — up 163% from $14.2M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ANEB positions and 0 closed out — a net gain of 2 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was 22NW LP, adding an estimated $16.6M. The largest seller was LVW Advisors, cutting an estimated $14K.
- 15 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q4 2024, up from 13 in Q3 2024.
- Funds reported $37.3M of Anebulo Pharmaceuticals stock for Q4 2024, up 163% quarter-over-quarter.
- 2 funds opened new Anebulo Pharmaceuticals positions in Q4 2024 and 0 closed out, a net change of +2 holders.
- The largest Anebulo Pharmaceuticals buyer in Q4 2024 was 22NW LP, an estimated $16.6M added.
- The largest Anebulo Pharmaceuticals seller in Q4 2024 was LVW Advisors, an estimated $14K sold.
Based on aggregated 13F filings for Q4 2024.